Related Experiment Video

Updated: Jun 24, 2026

Production and Titering of Recombinant Adeno-associated Viral Vectors
08:35

Production and Titering of Recombinant Adeno-associated Viral Vectors

Published on: November 27, 2011

Promises of co-stimulatory inhibition for durable and repeatable AAV gene therapy

Klaudia Kuranda1, David Alexandre Gross2, Giuseppe Ronzitti2

  • 1Genethon, 91000 Evry, France.

Molecular Therapy : the Journal of the American Society of Gene Therapy
|June 22, 2026
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Production of Adeno-Associated Virus Vectors in Cell Stacks for Preclinical Studies in Large Animal Models
07:21

Production of Adeno-Associated Virus Vectors in Cell Stacks for Preclinical Studies in Large Animal Models

Published on: June 30, 2021

Related Experiment Videos

Last Updated: Jun 24, 2026

Production and Titering of Recombinant Adeno-associated Viral Vectors
08:35

Production and Titering of Recombinant Adeno-associated Viral Vectors

Published on: November 27, 2011

Production of Adeno-Associated Virus Vectors in Cell Stacks for Preclinical Studies in Large Animal Models
07:21

Production of Adeno-Associated Virus Vectors in Cell Stacks for Preclinical Studies in Large Animal Models

Published on: June 30, 2021

Related Concept Videos

Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...

Articles linked to this work by shared authors, journal, and citation graph.

Gene supplementation therapy restores motor deficits in Gnao1[C215Y] mice and proves broad efficacy in C. elegans model.

Acta neuropathologica communications·2026

Rapamycin nanoparticles mitigate anti-AAV antibody formation in a mouse model of ornithine transcarbamylase deficiency.

Molecular therapy. Advances·2026

CD8+ T cell activation occurs 24 hours after AAV administration and is driven by muscle promoter specificity.

JCI insight·2026

Intravitreal AAV vector delivery induces integrin-dependent ocular inflammation, complement activation, and antiviral and DNA damage responses.

Frontiers in immunology·2026

CRISPR-Cas9-mediated upregulation of utrophin ameliorates Duchenne muscular dystrophy.

Molecular therapy : the journal of the American Society of Gene Therapy·2026

Interindividual variability in immune response to AAV ocular gene delivery across species impedes immunomonitoring.

JCI insight·2026

Pre-clinical validation of AAV-mediated gene therapy for KCNV2 retinopathy improves visual function and expression in mouse and patient models.

Molecular therapy : the journal of the American Society of Gene Therapy·2026

LNP-formulated dbDNA™ vaccines elicit durable humoral and cellular immunity with distinct kinetics to mRNA in non-human primates.

Molecular therapy : the journal of the American Society of Gene Therapy·2026

Targeted Epigenetic Reactivation strategies as new treatments for Prader-Willi Syndrome: Achievements and Challenges.

Molecular therapy : the journal of the American Society of Gene Therapy·2026

Catestatin peptide ameliorates tauopathy and amyloidogenesis via adrenergic inhibition.

Molecular therapy : the journal of the American Society of Gene Therapy·2026

p38 MAPK inhibition safeguards genome integrity during gene editing of hematopoietic stem and progenitor cells.

Molecular therapy : the journal of the American Society of Gene Therapy·2026

Development of CRISPR_SCD001, an Autologous Hematopoietic Stem Cell Gene Therapy for Sickle Cell Disease after CRISPR-Cas9 Mediated Correction.

Molecular therapy : the journal of the American Society of Gene Therapy·2026

AI-enabled HRM systems in business organizations: effects on workforce outcomes and the roles of trust and privacy.

Frontiers in artificial intelligence·2026

Reconciling global collaboration and data sovereignty in neuroscience.

Nature neuroscience·2026

Fast Fixed-Time Scaled Bipartite Consensus Control for High-Order Multiagent Systems With Time-Varying Extended State Observer.

IEEE transactions on cybernetics·2026

Does experience modulate automatic imitation? A new look.

PloS one·2026

Implementing a Cognitively Grounded Artificial Moral Advisor: A Multi-LLM Multi-Agent Approach Based on the Cognitive-Reflective Equilibration Model.

Journal of Intelligence·2026

The effect of auto-verification on turnaround time for clinical chemistry and immunoassay tests.

Journal of medical biochemistry·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us